Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.47 |
| ▸ | CDK2 | P24941 | 13/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998533 | 0.87 | GSK3B (0.51) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL13885051 | 0.85 | GSK3B (0.65) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL14528908 | 0.85 | GSK3B (0.59) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL13998487 | 0.81 | GSK3B (0.52) | GSK3BCDK2CCNE1 | |
| SCHEMBL13993126 | 0.74 | CDK2 (0.67) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL12953407 | 0.74 | CDK2 (0.46) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL14043298 | 0.74 | CDK2 (0.46) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL14528750 | 0.72 | GSK3B (0.43) | GSK3BCDK2MAPKAPK2 | |
| SCHEMBL13893796 | 0.71 | GSK3B (0.61) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL16784405 | 0.71 | GSK3B (0.61) | GSK3BCDK2CHEK1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934224-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |